SEARCH

SEARCH BY CITATION

References

  • Akaza H, Yamaguchi A, Matsuda T, Igawa M, Kumon H & Soeda A et al. (2004) Superior anti-tumor efficacy of bicalutamide 80 mg in combination with a luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist monotherapy as first-line treatment for advanced prostate cancer: Interim results of a randomized study in Japanese patients. Jpn J Clin Oncol 34, 2028.
  • Bonkhoff H & Berges R. (2009) The evolving role of oestrogens and their receptors in the development and progression of prostate cancer. Eur Urol 55, 533542.
  • Bonkhoff H, Fixemer T, Hunsicker I & Remberger K. (1999) Estrogen receptor expression in prostate cancer and premalignant prostatic lesions. Am J Pathol 155, 641647.
  • De Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP & Kocak I et al. (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376, 11471154.
  • Decensi A, Torrisi R, Fontana V, Marroni P, Padovani P & Guarneri D et al. (1993) Long-term endocrine effects of administration of either a non-steroidal antiandrogen or a luteinizing hormone-releasing hormone agonist in men with prostate cancer. Acta Endocrinol 129, 315321.
  • Ellem SJ & Risbridger GP. (2010) Aromatase and regulating the estrogen: androgen ratio in the prostate gland. J Steroid Biochem Mol Biol 118, 246251.
  • Ellem SJ, Wang H, Poutanen M & Risbridger GP. (2009) Increased endogenous estrogen synthesis leads to the sequential induction of prostatic inflammation (prostatitis) and prostatic pre-malignancy. Am J Pathol 175, 11871199.
  • Ferro MA, Gillatt D, Symes MO & Smith PJ. (1989) High-dose intravenous estrogen therapy in advanced prostatic carcinoma. Use of serum prostate-specific antigen to monitor response. Urology 34, 134138.
  • Fixemer T, Remberger K & Bonkhoff H. (2003) Differential expression of the estrogen receptor β (ER β) in human prostate tissue, premalignant changes, and in primary, metastatic, and recurrent prostatic adenocarcinoma. Prostate 54, 7987.
  • Giton F, de la Taille A, Allory Y, Galons H, Vacherot F & Soyeux P et al. (2008) Estrone sulfate (E1S), a prognosis marker for tumor aggressiveness in prostate cancer (PCa). J Steroid Biochem Mol Biol 109, 158167.
  • Ho CK, Nanda J, Chapman KE & Habib FK. (2008) Oestrogen and benign prostatic hyperplasia: effects on stromal cell proliferation and local formation from androgen. J Endocrinol 197, 483491.
  • Isaacs JT & Coffey DS. (1981) Adaptation vs selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the dunning R-3327-H adenocarcinoma. Cancer Res 41, 50705075.
  • Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ & Penson DF et al. (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363, 411422.
  • Keto CJ, Aronson WJ, Terris MK, Presti JC, Kane CJ & Amling CL et al. (2011) Obesity is associated with castration-resistant disease and metastasis in men treated with androgen deprivation therapy after radical prostatectomy: results from the SEARCH database. BJU Int 10, 492498.
  • Kim IY, Kim BC, Seong DH, Lee DK, Seo JM & Hong YJ et al. (2009) Raloxifene, a mixed estrogen agonist/antagonist, induces apoptosis in androgen-independent human prostate cancer cell lines. Cancer Res 62, 53655369.
  • Klotz L, Schellhammer P & Carroll K. (2004) A reassessment of the role of combined androgen blockade for advanced prostate cancer. BJU Int 93, 11771182.
  • Kruithof-Dekker IG, Têtu B, Janssen PJ & Van der Kwast TH. (1996) Elevated estrogen receptor expression in human prostatic stromal cells by androgen ablation therapy. J Urol 156, 11941197.
  • Leav I, Lau KM, Adams JY, McNeal JE, Taplin ME & Wang J et al. (2001) Comparative studies of the estrogen receptors β and α and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma. Am J Pathol 159, 7992.
  • Meyer MR, Prossnitz ER & Barton M. (2011) The G protein-coupled estrogen receptor GPER/GPR30 as a regulator of cardiovascular function. Vascul Pharmacol 55, 1725.
  • Montgomery B, Nelson PS, Vessella R, Kalhorn T, Hess D & Corey E. (2010) Estradiol suppresses tissue androgens and prostate cancer growth in castration resistant prostate cancer. BMC Cancer 10, 244250.
  • Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M & Matveev V et al. (2011) EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 59, 572583.
  • Nelles JL, Hu WY & Prins GS. (2011) Estrogen action and prostate cancer. Expert Rev Endocrinol Metab 6, 437451.
  • Parker C, Heinrich D, O'Sullivan JM, Fossa SD, Chodacki A & Demkow T et al. (2012) Overall survival benefit and safety profile of radium-223 chloride, a first-in-class alpha-pharmaceutical: Results from a phase III randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) with bone metastases. J Clin Oncol 30 (Suppl. 5), abstr 8.
  • Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA & Taplin ME et al. (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351, 15131520.
  • Robertson CN, Roberson KM, Padilla GM, O'Brien ET, Cook JM & Kim CS et al. (1996) Induction of apoptosis by diethylstilbestrol in hormone-insensitive prostate cancer cells. J Natl Cancer Inst 88, 908917.
  • Salonia A, Gallina A, Briganti A, Suardi N, Capitanio U & Abdollah F et al. (2011) Circulating estradiol, but not testosterone, is a significant predictor of high-grade prostate cancer in patients undergoing radical prostatectomy. Cancer 117, 50295038.
  • Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN & Carducci MA et al. (2008) Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the prostate cancer clinical trials working group. J Clin Oncol 26, 11481159.
  • Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN & Miller K et al. (2012) Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: Results from the phase III AFFIRM study. J Clin Oncol 30 (Suppl. 5), abstr LBA1.
  • Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A & Chi KN et al. (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351, 15021512.
  • Wang C, Nieschlag E, Swerdloff R, Behre HM, Hellstrom WJ & Gooren LJ et al. (2009) Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. Eur Urol 55, 121130.